Adipokines and cardiovascular risk in cushing's syndrome

Neuroendocrinology

Volumn 95, Issue 3, 2012, Pages 187-206

  Valassi, Elena ^a   Biller, Beverly M K ^a   Klibanski, Anne ^a   Misra, Madhusmita ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adipokines; Cardiovascular risk; Cushing's syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ADIPONECTIN; ANGIOTENSINOGEN; C REACTIVE PROTEIN; CORTICOTROPIN; DEXAMETHASONE; GHRELIN; HYDROCORTISONE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; MESSENGER RNA; PREDNISOLONE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTERIAL STIFFNESS; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY CALCIFICATION; CORTICOTROPIN RELEASE; CUSHING SYNDROME; ENZYME ACTIVITY; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCONEOGENESIS; GROWTH HORMONE DEFICIENCY; HEART FAILURE; HEART INFARCTION; HORMONE RELEASE; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEX DIFFERENCE;

ADIPOKINES; CARDIOVASCULAR DISEASES; CUSHING SYNDROME; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LEPTIN; PITUITARY-ADRENAL SYSTEM; RISK FACTORS;

EID: 84860743806     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000330416     Document Type: Article

References (196)

1. Newell-Price J, Trainer P, Besser M, Grossman A: The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19: 647-672. (Pubitemid 28467716)
2. Extabe J, Vazquez JA: Morbidity and mortality in Cushing's disease: An epidemiological approach. Clin Endocrinol 1994; 40: 479-484. (Pubitemid 24194645)
3. Pivonello R, Faggiano A, Lombardi G, Colao A: The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005; 34: 327-339. (Pubitemid 40602724)
4. Halberg N, Wernstedt-Asterholm I, Scherer PE: The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 2008; 37: 753-768.
5. Wajchenberg BL, Bosco A, Martins Marone M, Levin R, Rocha M, Lerario AC: Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 1995; 80: 2791-2794.
6. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP, Besser GM, Grossman AB, Reznek RH: Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol 2003; 149: 561-567. (Pubitemid 38054701)
7. Garrapa GGM, Pantanetti P, Arnaldi G, Mantero F, Faloia E: Body composition and metabolic features in women with adrenal incidentaloma or Cushing's disease. J Clin Endocrinol Metab 2001; 86: 5301-5306. (Pubitemid 33070251)
8. Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP: Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. J Clin Endocrinol Metab 1994; 78: 131-137. (Pubitemid 24026761)
9. Tzanela M, Karavitaki N, Stylianidou C, Tsagarakis S, Thalassinos N: Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome. Clin Endocrinol 2004; 60: 309-314. (Pubitemid 38297120)
10. Pecori Giraldi F, Andrioli M, De Marinis L, Bianchi A, Giampietro A, De Martin M, Sacco E, Scacchi M, Pontecorvi A, Cavagnini F: Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease. Eur J Endocrinol 2007; 156: 233-239. (Pubitemid 46554518)
11. Senaris RM, Lago F, Coya R, Pineda J, Dieguez C: Regulation of hypothalamic somatostatin, growth-hormone releasing hormone, and growth hormone receptor messenger ribonucleic acid by glucocorticoids. Endocrinology 1996; 137: 5236-5241. (Pubitemid 26423079)
12. Wehrenberg WB, Bergman PJ, Staag L, Ndon G, Giustina A: Glucocorticoid inhibition of growth hormone in rats: Partial reversal with somatostatin antibodies. Endocrinology 1990; 127: 2705-2708.
13. Leal-Cerro A, Soto A, Martinez MA, Alvarez P, Isidro L, Casanueva F, Dieguez C, Cordido F: Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone is a stimulus of GH secretion in Cushing's syndrome. Clin Endocrinol 2002; 57: 745-749. (Pubitemid 36963002)
14. Colao A, Pivonello R, Spiezia A, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G: Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84: 2664-2672. (Pubitemid 30641990)
15. Burt MG, Gibney J, Ho KKY: Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: A study of body composition and energy metabolism. Clin Endocrinol 2006; 64: 436-443.
16. Webb SM, Mo D, Lamberts SWJ, Melmed S, Cavagnini F, Pecori Giraldi F, Strasburger CJ, Zimmermann AG, Woodmansee WW, on behalf of the International HypoCCS Advisory Board: Metabolic, cardiovascular, and cerebrovascular outcomes in growthhormone deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab 2010; 95: 630-638.
17. Höybye C, Ragnarsson O, Jönsson PJ, Koltowska- Häggström P, Trainer P, Feldt-Rasmussen U, Biller BM: Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease. Eur J Endocrinol 2010; 162: 677-684.
18. Johannsson G, Stibrant Sunnerhagen K, Svensson J: Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clin Endocrinol 2004; 60: 550-559. (Pubitemid 38678637)
19. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295. (Pubitemid 26033933)
20. Martin SS, Qasim A, Reilly MP: Leptin resistance: A possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52: 1201-1210.
21. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzmán M, Brownlee M: Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2003; 276: 25096-25100.
22. O'Rourke L, Gronning LM, Yeman SJ, Shepherd PR: Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 2002; 277: 42557-42562. (Pubitemid 35285623)
23. Qasim A, Mehta N, Tadesse MG, Wolfe ML, Rhodes T, Girman G, Reilly MP: Adipokines, insulin resistance and coronary artery calcification. J Am Coll Cardiol 2008; 52: 231-236. (Pubitemid 351915780)
24. Singh P, Hoffmann M, Wolk R, Shamsuzzaman AS, Somers VK: Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2008; 27:e302-e307.
25. Wallace AM, Mc Mahon AD, Pacjard CJ, Kelly A, Shepherd J, Graw A, Sattar N: Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001; 104: 3052-3056. (Pubitemid 34014056)
26. Heiman ML, Ahima RS, Craft LS, Schoner B, Stephens TW, Flier JS: Leptin inhibition of the hypothalamic-pituitary-Adrenal axis in response to stress. Endocrinology 1997; 138: 3859-3863. (Pubitemid 27351940)
27. Raber J, Chen S, Mucke L, Feng L: Corticotropin-releasing factor and adrenocorticotrophic hormone as potential central mediators of OB effects. J Biol Chem 1997; 272: 15057-15060. (Pubitemid 27255516)
28. Pralong FP, Roduit R, Waeber G, Castillo E, Mosimann F, Thorens B, Gaillard RC: Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland. Endocrinology 1998; 139: 4264-4268. (Pubitemid 28513714)
29. Liu Y, Nakagawa Y, Wang Y, Li R, Ohzeki T, Friedman TC: Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin deficient ob/ob mice. Diabetes 2003; 52: 1409-1416. (Pubitemid 36666195)
30. Malendowicz L, Rucinski M, Belloni A, Ziolkowska A, Nussedorfer G: Leptin and the regulation of the hypothalamic-pituitaryadrenal axis. Int Rev Cytol 2007; 263: 63-102.
31. Uehara Y, Shimizu H, Ohtani K, Sato N, Mori M: Hypothalamic corticotropin-releasing hormone is a mediator of anorexigenic effect of leptin. Diabetes 1998; 47: 890-893. (Pubitemid 28255661)
32. Nishiyama M, Makino S, Asaba K, Hashimoto K: Leptin effects on the expression of type-2 CRH receptor mRNA in the ventromedial hypothalamus in the rat. J Neuroendocrinol 1999; 11: 307-314. (Pubitemid 29149885)
33. Arvaniti K, Huang Q, Richard D: Effects of leptin and corticosterone on the expression of corticotrophin-releasing hormone, agouti-related protein, and proopiomelanocortin in the brain of ob/ob mouse. Neuroendocrinology 2007; 73: 227-236.
34. Jang M, Mistry A, Swick AG, Romson DR: Leptin rapidly inhibits hypothalamic neuropeptide Y secretion and stimulates corticotrophin-releasing hormone secretion in adrenalectomized mice. J Nutr 2007; 130: 2813-2820.
35. Renz M, Tomlison E, Hultgren B, Levin N, Gu QM, Shimkets RA, Lewin DA, Stewart TA: Quantitative expression analysis of genes regulated by both obesity and leptin reveals a regulatory loop between leptin and pituitary-derived ACTH. J Biol Chem 2000; 275: 10429-10436. (Pubitemid 30202103)
36. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, Kriauciunas A, MacKellar W, Rosteck PR, Schoner B, Smith D, Tinsley FC, Zhang XY, Heiman M: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995; 377: 530-532.
37. Iwasaki T, Takayasu S, Nishiyama M, Tsugita M, Taguchi T, Asai M, Yoshida M, Kambayashi M, Hashimoto M: Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-Activating enzyme (11 -hydroxysteroid dehydrogenase type 1) gene. Mol Cell Endocrinol 2008; 285: 10-18.
38. Licinio J, Mantzoros C, Negrao CB, Cizza G, Wong ML, Bongiorno PB, Chrousos GP, Karp B, Allen C, Flier JS, Gold PW: Human leptin levels are pulsatile and inversely related to pituitary-Adrenal function. Nat Med 1997; 3: 575-579. (Pubitemid 27198660)
39. Koutkia P, Canavan B, Johnson ML, De Paoli A, Grinspoon S: Characterization of leptin pulse dynamics and relationship to fat mass, growth hormone, cortisol, and insulin. Am J Physiol Endocrinol Metab 2003; 285:E372-E379. (Pubitemid 36899711)
40. Casabiell X, Pineiro V, Peino R, Lage M, Camina J, Gallego R, Vallejo LG, Dieguez C, Casanueva FF: Gender differences in both spontaneous and stimulated leptin secretion by human omental adipose tissue in vitro: Dexamethasone and estradiol stimulate leptin release in women, but not in men. J Clin Endocrinol Metab 1998; 83: 2149-2155. (Pubitemid 28496352)
41. Miell JP, Englaro P, Blum WF: Dexamethasone induces an acute and sustained rise in circulating leptin levels in normal human subjects. Horm Metab Res 1996; 28: 704-707. (Pubitemid 27057920)
42. Newcomer JW, Selke G, Melson AK, Gross J, Vogler GP, Dagogo-Jack S: Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. Arch Gen Psychiatry 1998; 55: 995-1000. (Pubitemid 28506841)
43. Dagogo-Jack S, Selke G, Melson AK, Newcomer JW: Robust leptin secretory responses to dexamethasone in obese subjects. J Clin Endocrinol Metab 1997; 82: 3230-3233. (Pubitemid 27419062)
44. Janssen JA, Huizenga NA, Stolk RP, Grobbee DE, Pols HA, De Jong FH, Attanasio AM, Blum WF, Lamberts SW: The acute effect of dexamethasone on plasma leptin concentrations and the relationships between fasting leptin, the IGF-I-IGFBP system, dehydroepiandrosterone, androstenedione and testosterone in an elderly population. Clin Endocrinol 1998; 48: 621-626. (Pubitemid 28252999)
45. Larsson H, Ahren B: Short-term dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women. J Clin Endocrinol Metab 1996; 81: 4428-4432. (Pubitemid 26412056)
46. Torpy DJ, Bornstein SR, Cizza G, Chrousos GP: The effects of glucocorticoids on leptin concentrations in humans may be restricted to acute pharmacological dosing. J Clin Endocrinol Metab 1998; 83: 1821-1822. (Pubitemid 28501067)
47. Tataranni P, Pratley R, Maffei M, Ravussin E: Acute and prolonged administration of glucocorticoids (methylprednisolone) does not affect plasma leptin concentration in humans. Int J Obes 1997; 21: 327-330. (Pubitemid 27158313)
48. Putignano P, Brunani A, Dubini A, Bertolini M, Pasquali R, Cavagnini F: Effect of small doses of dexamethasone on plasma leptin levels in normal and obese subjects: A doseresponse study. J Endocrinol Invest 2003; 26: 111-116. (Pubitemid 36503056)
49. Rosenbaum M, Pietrobelli A, Vasselli JR, Heymsfield SB, Leibel RL: Sexual dimorphism in circulating leptin concentrations is not accounted for by differences in adipose tissue distribution. Intern J Obes 2001; 25: 1365-1371. (Pubitemid 32835456)
50. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonqvist F, Arner P: Leptin secretion and from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913-917. (Pubitemid 28255665)
51. Elbers JMH, Asscheman H, Seidell JC, Frölich M, Meinders AE, Gooren LJG: Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration on transsexuals. J Clin Endocrinol Metab 1997; 82: 3267-3270. (Pubitemid 27419069)
52. Cohen P, Yang G, Xu X, Soukas AA, Wolfish CS, Friedman JM: Induction of leptin receptor expression in the liver by leptin and food deprivation. J Biol Chem 2005; 280: 10034-10039. (Pubitemid 40395854)
53. Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS: Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids and leptin. Diabetes 2002; 51: 2105-2112.
54. Misra M, Miller KK, Almazan C, Ramaswamy K, Aggarwal A, Herzog DB, Neubauer G, Breu J, Klibanski A: Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. J Clin Endocrinol Metab 2004; 89: 3486-3495. (Pubitemid 38951925)
55. Gavrila A, Peng CK, Chan L, Mietus JE, Goldberger AL, Mantzoros CS: Diurnal and ultradian dynamics of serum adiponectin in healthy men: Comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003; 88: 2838-2843. (Pubitemid 36724465)
56. Leal-Cerro A, Considine RV, Peino R, Venegas E, Astorga R, Casanueva FF, Dieguez C: Serum immunoreactive-leptin levels are increased in patients with Cushing's syndrome. Horm Metab Res 1996; 28: 711-713. (Pubitemid 27057922)
57. Masuzaki H, Ogawa Y, Hosoda K, Miyawaki T, Hanakoa I, Yasuno A, Nishimura H, Yoshimasa Y, Nishi S, Nakao K: Glucocorticoid regulation of leptin synthesis and secretion in humans: Elevated plasma leptin levels in Cushing's syndrome. J Clin Endocrinol Metab 1997; 82: 2542-2547. (Pubitemid 27337870)
58. Cizza G, Lotsikas AJ, Licinio J, Gold PW, Chrousos GP: Plasma leptin levels do not change in patients with Cushing's disease shortly after correction of hypercorticolism. J Clin Endocrinol Metab 1997; 82: 2747-2750. (Pubitemid 27337904)
59. Weise M, Abad V, Considine RV, Nieman L, Rother KI: Leptin secretion in Cushing's syndrome: Preservation of diurnal rhythm and absent response to corticotrophin-releasing hormone. J Clin Endocrinol Metab 1999; 84: 2075-2079. (Pubitemid 30647036)
60. Widjaja A, Schurmeyer TH, Von zur Muhlen A, Brabant G: Determinants of serum leptin levels in Cushing's syndrome. J Clin Endocrinol Metab 1998; 83: 600-603. (Pubitemid 28496545)
61. Veldman RG, Frolich M, Pincus SM, Veldhius JD, Roelfsema F: Hyperleptinemia in women with Cushing's disease is driven by high-Amplitude pulsatile, but orderly and eurhythmic, leptin secretion. Eur J Endocrinol 2001; 144: 21-27. (Pubitemid 32126908)
62. Grottoli S, Gauna C, Tassone F, Aimaretti G, Corneli G, Wu Z, Strasburger CJ, Diegeuez C, Casanueva FF, Ghigo E, Maccario M: Both fasting-induced leptin reduction and GH increase are blunted in Cushing's syndrome and in simple obesity. Clin Endocrinol 2003; 58: 220-228. (Pubitemid 36194278)
63. Kresk M, Silha JV, Jezkova J, Hana V, Marek J, Weiss V, Stepan JJ, Murphy LJ: Adipokine levels in Cushing's syndrome; elevated resistin levels in female patients with Cushing's syndrome. Clin Endocrinol 2004; 60: 350-357. (Pubitemid 38297126)
64. Van Dielen FMH, Van Veer C, Buurman WA, Greve JWM: Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J Clin Endocrinol Metab 2002; 87: 1708-1716. (Pubitemid 34615260)
65. Boden G, Chen X, Kolaczynski JW, Polansky M: Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J Clin Invest 1997; 100: 1107-1113. (Pubitemid 27386294)
66. Carantoni M, Abbasi F, Azhar S, Schaaf P, Reaven GM: Can changes in plasma insulin concentration explain the variability in leptin response to weight loss in obese women with normal glucose tolerance? J Clin Endocrinol Metab 1999; 84: 869-872. (Pubitemid 29138210)
67. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS: Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: Effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996; 81: 4406-4413. (Pubitemid 26412052)
68. Ueland T, Kristo C, Godang K, Aukrust P, Bollerslev J: Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome: A longitudinal study. J Clin Endocrinol Metab 2003; 88: 1492-1496. (Pubitemid 36623359)
69. Isosaki O, Tsushima T, Miyakawa M, Nozoe Y, Demura H, Seki H: Growth hormone directly inhibits leptin gene expression in visceral fat tissue in fatty Zucker rats. J Endocrinol 1999; 161: 511-516. (Pubitemid 29278807)
70. Fisker S, Vahl N, Hansen TB, Jorgensen JOL, Hagen C, Orskow H, Christiansen, JS: Serum leptin is increased in growth hormone-deficient adults: Relationship to body composition and effects of placebo-controlled growth hormone therapy for one year. Metabolism 1996; 46: 812-817.
71. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte D Jr, Woods SC, Seeley RJ, Weigle DS: Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996; 45: 531-535. (Pubitemid 26111317)
72. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ: Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes; effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002; 87: 5662-5667. (Pubitemid 36034375)
73. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE: Structure-function studies of the adipocytes-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085. (Pubitemid 36800387)
74. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudio K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with body lipoatrophy and obesity. Nat Med 2001; 7: 941-946. (Pubitemid 32756432)
75. Basu R, Pajvani UB, Rizza RA, Scherer PE: Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: Differential regulation from nondiabetic subjects. Diabetes 2007; 56: 2174-2177. (Pubitemid 47195840)
76. Hara K, Horikoshi M, Yamauchi T, Yago Y, Miyazaki O, Ebinuma H, Imai Y, Nagai R, Kadowaki T: Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2009; 29: 1357-1362. (Pubitemid 44125935)
77. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida H, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063. (Pubitemid 32200177)
78. Tan KCB, Xu A, Chow WS, Lam MCW, Ai VHG, Tam SG, Lam KLS: Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89: 765-769. (Pubitemid 38269891)
79. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-1089. (Pubitemid 34687474)
80. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737. (Pubitemid 38489895)
81. Makimura H, Mizuno TM, Bergen H, Mobbs CV: Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab 2002; 283:E1266-E1271. (Pubitemid 35340634)
82. Morton NM, Seckl JR: 11 -Hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008; 36: 146-164.
83. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS: Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005; 54: 1023-1031. (Pubitemid 40446315)
84. Patel JV, Cummings DE, Girod JP, Mascarenhas AV, Hughes EA, Gupta M, Lip GY, Reddy S, Brotman DJ: Role of metabolically active hormones in the insulin-resistance associated with short-term glucocorticoid treatment. J Negat Results Med 2006; 5: 14-19.
85. Lewandowski KC, Szosland K, Lewinski A: Short-term dexamethasone administration does not alter serum adiponectin or resistin concentrations in overweight and obese subjects despite an increase in insulin resistance. Clin Endocrinol 2005; 62: 30-36.
86. Rieth N, Jollin L, Le Panse B, Lecoq AM, Arlettaz A, De Ceaurriz J, Collomp K: Effects of short-term corticoid ingestion on food intake and adipokines in healthy recreationally trained men. Eur J Appl Physiol 2009; 105: 309-313.
87. Fallo F, Scarda A, Sonino N, Paoletta A, Boscaro M, Pagano C, Federspil G, Vettor R: Effect of glucocorticoids on adiponectin: A study in healthy subjects and in Cushing's syndrome. Eur J Endocrinol 2004; 150: 339-344. (Pubitemid 38443784)
88. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G: Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor- expression. Diabetes 2003; 52: 1779-1785. (Pubitemid 36792470)
89. Libè R, Morpugo PS, Cappiello V, Maffini A, Bondioni S, Locatelli M, Zavanone M, Beck-Peccoz P, Spada A: Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery. Clin Endocrinol 2005; 62: 30-36. (Pubitemid 40175280)
90. Barahona MJ, Sucunza N, Resmini E, Fernandez-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J, Webb SM: Persistent body fat mass and inflammatory marker increase after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab 2009; 94: 3365-3371.
91. Fukuda I, Hizuka H, Ishikawa Y, Itoh E, Yasumoto K, Murakami Y, Sata A, Tsukada J, Kurimoto M, Okubo Y, Takano K: Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth Horm IGF Res 2004; 14: 449-454. (Pubitemid 40298325)
92. Giavoli C, Cappiello V, Corbetta S, Ronchi CL, Morpurgo PS, Ferrante E, Beck-Peccoz P, Spada A: Different effects of short-And long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. Clin Endocrinol 2004; 61: 81-87. (Pubitemid 38951649)
93. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312. (Pubitemid 32151228)
94. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton CD, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulates by PPAR - Activators. Biochem Biophys Res Commun 2003; 300: 472-476. (Pubitemid 38375833)
95. Ukkola O: Resistin - A mediator of obesityassociated insulin resistance or an innocent bystander? Eur J Endocrinol 2002; 147: 571-574. (Pubitemid 35414553)
96. Calabro P, Samudio I, Willerson JT, Yeh ET: Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335-3340. (Pubitemid 39557496)
97. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsonomiya K, Nagai R: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415-419. (Pubitemid 38084733)
98. Meilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939. (Pubitemid 40279897)
99. Windham BG, Griswold ME, Farasat SM, Ling SM, Carlson O, Egan JM, Ferrucci L, Najjar SS: Influence of leptin, adiponectin, and resistin on the association between abdominal adiposity and arterial stiffness. Am J Hypertens 2010; 23: 501-507.
100. McManus DD, Lyass A, Ingelsson E, Massaro JM, Meigs JB, Aragam J, Benjamin EJ, Vasan RS: Relations of circulating resistin and adiponectin and cardiac structure and function: The Framingham Offspring Study. Obesity (Silver Spring) 2011 (E-pub ahead of print).
101. Frankel DS, Vesan RS, D'Agostino RB, Benjamin EJ, Levy D, Wang TJ, Meigs JB: Resistin, adiponectin, and risk of heart failure: The Framingham Offspring Study. J Am Coll Cardiol 2009; 53: 754-762.
102. Weikert C, Westphal S, Berger K, Dierkes J, Möhlig M, Spranger J, Rimm EB, Willich SN, Boeing H, Pischon T: Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008; 93: 2647-2653. (Pubitemid 352008532)
103. Rajpathak SN, Kaplan RC, Wassertheil-Smoller S, Cushman M, Rohan TE, Mc-Ginn AP, Wang T, Strickler HD, Scherer PE, Mackey R, Curb D, Ho GY: Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: Results from the Women's Health Initiative. Stroke 2011 (Epub ahead of print).
104. Shojima N, Sakoda H, Ogihara T, Fujshiro M, Katagiri H, Anai M, Onishi Y, Ono H, Inukai K, Abe M, Fukushima Y, Kikuchi M, Oka Y, Asano T: Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002; 51: 1737-1744. (Pubitemid 34564285)
105. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Tumor necrosis factor- is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001; 9: 1027-1031. (Pubitemid 33140987)
106. Brown R, Wiesner G, Ur E, Wilkinson M: Pituitary resistin gene expression is upregulated in vitro and in vivo by dexamethasone but is unaffected by rosiglitazone. Neuroendocrinology 2005; 81: 41-48. (Pubitemid 40868726)
107. Nogueiras R, Gallego R, Gualillo O, Caminos JE, Garcia-Caballero T, Casanueva FF, Dieguez C: Resistin is expressed in different rat tissues and is regulated in a tissueand gender-specific manner. FEBS Lett 2003; 548: 21-27. (Pubitemid 37281244)
108. Ermetici F, Malavazos AE, Corbetta S, Morricone L, Dall'Asta C, Corsi MM, Ambrosi B: Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism 2007; 56: 686-692. (Pubitemid 46574732)
109. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy LJ: The effects of GH replacement in adult GH-deficient patients: Changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol 2004; 60: 442-450. (Pubitemid 38482506)
110. Fasshauer M, Klein J, Krahlisch S, Lossner U, Klier M, Bluher M, Paschke R: GH is a positive regulator of tumor necrosis factor-induced adipose related protein in 3T3-L1 adipocytes. J Endocrinol 2003; 178: 523-531. (Pubitemid 37220178)
111. Hotamisligil G, Arner P, Caro J, Atkinson R, Spiegelman B: Increased adipose tissue expression of tumor necrosis factor- in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
112. Yudkin JS, Eringa E, Stehouwer CD: 'Vasocrine'signaling from perivascular fat: A mechanism linking insulin resistance to vascular disease. Lancet 2005; 365: 1817-1820. (Pubitemid 40744663)
113. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
114. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor B: Inflammatory markers and onset of cardiovascular events: Results from the Health ABC Study. Circulation 2003; 108: 2317-2322. (Pubitemid 37413536)
115. Ridker PM, Rifai N, Pfeifer M, Sacks F, Lepage S, Braunwald E: Elevation of tumor necrosis factor- and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-2153. (Pubitemid 30253042)
116. Swain MG, Appleyard CB, Wallace JL, Maric M: TNF- facilitates inflammationinduced glucocorticoid secretion in rats with biliary obstructions. J Hepatol 1997; 26: 361-368. (Pubitemid 27077436)
117. Artz E, Kovalovsky D, Igaz LM, Costas M, Plazas P, Refojo D, Paez Pereda M, Reul JM, Stalla G, Holsboer F: Functional cross-talk among cytokines, T-cell receptor, and glucocorticoid receptor transcriptional activity and action. Ann N Y Acad Sci 2009; 917: 672-677.
118. Bernardini R, Kamilaris TC, Calogero AE, Johnson EO, Gomez MT, Gold PW, Chrousos GP: Interactions between tumor necrosis factor- , hypothalamic corticotrophinreleasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 1990; 126: 2876-2881. (Pubitemid 20216538)
119. Gaillard RC, Turnill D, Sappino P, Muller AF: Tumor necrosis factor- inhibits the hormonal response of the pituitary gland to hypothalamic releasing factors. Endocrinology 1990; 127: 101-106. (Pubitemid 20228107)
120. Judd AM, Call GB, Barney M, McImoil CJ, Balls AG, Adams A, Oliveira GK: Possible function of IL-6 and TNF as intra-Adrenal factors in the regulation of adrenal steroid secretion. Ann N Y Acad Sci 2000; 917: 628-637.
121. Bujalska LJ, Kumar S, Stewart PM: Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 1997; 349: 1210-1213. (Pubitemid 27190044)
122. Sewter CP, Digby JE, Blows F, Prins J, O'Rahilly S: Regulation of tumour necrosis factor- release from human adipose tissue in vitro . J Endocrinol 1999: 163: 33-38. (Pubitemid 29481300)
123. Zilberfarb V, Siquier Q, Strosberg AD, Issad T: Effect of dexamethasone on adipocyte differentiation markers and tumor necrosis factor- expression in human PAZ6 cells. Diabetologia 2003; 44: 377-386.
124. Elenkov IJ, Chrousos GP: Stress hormones, pro-inflammatory and anti-inflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 2002; 966: 290-303.
125. Zawacki JK, Hunt JL, Gamelli RL, Filkins JP: Glucocorticoid regulation of hepatic TNF production following cecal ligation and puncture sepsis. Shock 1997; 8: 141-145. (Pubitemid 127654319)
126. Patel JV, Cummings DE, Girod JP, Mascarenhas AV, Hughes EA, Gupta M, Lip GY, Reddy S, Brotman DJ: Role of metabolically active hormones in the insulin resistance associated with short-term glucocorticoid treatment. J Negat Results Biomed 2006; 11: 5-14.
127. DeRijk R, Michelson D, Karp B, Petrides J, Galliven E, Deuster P, Paciotti G, Gold PW, Sternberg EM: Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin (IL)-1 - , IL-6, and tumor necrosis factor- (TNF- ) production in humans: High sensitivity of TNF- and resistance of IL-6. J Clin Endocrinol Metab 1997; 82: 2182-2191. (Pubitemid 27287581)
128. Russell M, Bredella M, Tsai P, Mendes N, Miller KK, Klibanski A, Misra M:
129. Papanicolau DA, Tsigos C, Oldfield EH, Chrousos GP: Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: Does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab 1996; 81: 2303-2306. (Pubitemid 26175961)
130. Kristo C, Godang K, Ueland T, Lien E, Aukrust P, Froland SS, Bollerslev J: Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing's syndrome. Eur J Endocrinol 2002; 146: 389-395. (Pubitemid 34257650)
131. Merola B, Longobardi S, Colao A, Di Somma C, Ferone D, Di Rella F, Pivonello R, Covelli V, Annunziato L, Lombardi G: Tumor necrosis factor- increases after corticotropin-releasing hormone administration in Cushing's disease. In vivo and in vitro studies. Neuroendocrinology 1996; 64: 393-397. (Pubitemid 26358647)
132. Chrousos GP: The hypothalamic-pituitary adrenal axis and the immune-mediated inflammation. N Engl J Med 1995; 332: 1351-1362.
133. Arikan S, Bahceci M, Tuzcu A, Gokalp D: Serum tumor necrosis factor- and interleukin-8 levels in acromegalic patients: Acromegaly may be associated with moderate inflammation. Clin Endocrinol 2009; 70: 498-501.
134. Serri O, St-Jacques P, Sartippour M, Renier G: Alteration of monocyte function in patients with GH deficiency: Effect of substitutive GH therapy. J Clin Endocrinol Metab 1999; 84: 58-63. (Pubitemid 29036680)
135. Mohamed-Ali V, Pinkney JK: Adipose tissue as an andocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 1145-1158. (Pubitemid 28548534)
136. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE: Circulating IL-6 in relation to adiposity, insulin action and insulin secretion. Obes Res 2001; 9: 414-417. (Pubitemid 33603868)
137. Fasshauer M, Paschke R: Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-1603. (Pubitemid 38005321)
138. Bastard JP, Jardel C, Bruckett E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B: Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85: 3338-3342.
139. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 1999; 148: 209-214.
140. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimowitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512. (Pubitemid 29231100)
141. Liuzzo G, Baisucci LM, Gallimore JR, Caligiuri G, Buffon A, Rebuzzi AG, Pepys MB, Maseri A: Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999; 34: 1696-1703.
142. Turnbull AV, Rivier CL: Regulation of the hypothalamic-pituitary adrenal axis by cytokines: Actions and mechanisms of action. Physiol Rev 1999; 79: 1-71. (Pubitemid 29056948)
143. Bethin KE, Vogt SK, Muglia LJ: Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA 2006; 97: 9317-9322.
144. Salas MA, Evans SW, Levell MJ, Whicher JT: Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin Exp Immunol 1990; 79: 470-473. (Pubitemid 20082279)
145. Pereda MP, Lohrer P, Kovalovsky D, Perez Castro C, Goldberg V, Losa M, Chervin A, Berner S, Molina H, Stalla GK, Renner U, Artz E: Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph pituitary adenomas. Exp Clin Endocrinol Diabetes 2000; 108: 202-207. (Pubitemid 30315899)
146. Sarlis NJ, Stephanou A, Knight RA, Lightman SL, Chowdrey HS: Effects of glucocorticoids and chronic inflammatory stress upon anterior pituitary interleukin-6 mRNA expression in the rat. Br J Rheumatol 1993; 32: 653-657. (Pubitemid 23249166)
147. Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoids. J Clin Endocrinol Metab 1998; 83: 847-850. (Pubitemid 28496456)
148. Papanicolau DA, Petrides JS, Tsigos C, Bina S, Kalogeras KT, Wilder R, Gold PW, Deuster PA, Chrousos GP: Exercise stimulates interleukin-6 secretion: Inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol 1996; 271:E601-E605.
149. Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-Adrenal axis in humans. J Clin Endocrinol Metab 1993; 77: 1690-1694. (Pubitemid 24000936)
150. Kushlinskii NE, Britvin TA, Kazantseva IA, Baronin AA, Polikarpova SB, Bogatyrev OP, Tishenina RS, Kalinin AP: Serum interleukin-6 in patients with adrenal tumors. Bull Exp Biol Med 2004; 137: 273-275. (Pubitemid 38801809)
151. Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamuru M, Ishigami T, Yabana M, Kihara M, Inoue S, Ishii M: Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997; 10: 629-633. (Pubitemid 27293478)
152. Van Harmelen V, Elizalde M, Ariapart P, Bergstedt-Lindqvist S, Reynisdottir S, Hoffstedt J, Lundkvist I, Bringman S, Arner P: The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int J Obes Relat Metab Disord 2000; 24: 673-678. (Pubitemid 30339263)
153. Kim S, Solatni-Bejnood M, Quignard-Boulange A, Massiera F, Teboul M, Ailhaud G, Kim JH, Moustaid-Moussa N, Voy BH: The adipose renin-Angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-Angiotensin system. J Biomed Biotech 2006; 2006: 27012.
154. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M: Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-2729.
155. Aubert J, Darimont C, Safonova I, Ailhaud G, Negrel R: Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells, Biochem J 1997; 328: 701-706. (Pubitemid 27515619)
156. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170. (Pubitemid 33150673)
157. Saint-Marc P, Kozac LP, Aihaud G, Darimont C, Negrel R: Angiotensin II as a trophic factor of white adipose tissue: Stimulation of adipose cell formation. Endocrinology 2001; 142: 487-492. (Pubitemid 32183711)
158. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM: Hormonal regulation of the human adipose-tissue renin-Angiotensin system: Relationship to obesity and hypertension. J Hypertens 2002; 20: 965-973. (Pubitemid 34913678)
159. Engeli S, Bohnke J, Feldpausch M, Gonzelniak K, Heintze U, Janke J, Luft FC, Sharma AM: Regulation of 11 -HSD genes in human adipose tissue: Influence of central obesity and weight loss. Obes Res 2004; 12: 9-17. (Pubitemid 41137482)
160. Haller H, Hensen J, Bahr V, Oelkers W: Effects of angiotensin II infusion on the early morning surge of ACTH and o-CRH-provoked ACTH secretion in normal man. Acta Endocrinol 1986; 112: 150-156. (Pubitemid 16062597)
161. Calogero AE, Fornito MC, Aliffi A, Vicari E, Moncada ML, Mantero F, Polosa P, D'Agata R: Role of peripherally infused angiotensin II on the human hypothalamicpituitary-Adrenal axis. Clin Endocrinol 1991; 34: 183-186.
162. Rayyis SS, Horton R: Effect of angiotensin II on adrenal and pituitary function in man. J Clin Endocrinol Metab 1971; 32: 539-546.
163. Semple PF, Buckingham JC, Mason PA, Fraser R: Suppression of plasma ACTH concentration by angiotensin II infusion in normal humans and in a subject with a steroid 17 -hydroxylase defect. Clin Endocrinol 1979; 10: 137-144. (Pubitemid 10168245)
164. Sanchez-Lemus E, Benicky J, Pavel J, Saavedra JM: In vivo angiotensin II AT(1) receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. Brain Behav Immun 2009; 296:R1376-R1384.
165. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S: Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62: 275-279. (Pubitemid 16121554)
166. Shibata H, Suzuki H, Maruyama T, Saruta T: Gene expression of angiotensin II receptor in blood cells of Cushing's syndrome. Hypertension 1995; 26: 1003-1010.
167. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Insulin resistance atherosclerosis study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137. (Pubitemid 34438360)
168. Juhan-Vague I, Alessi MC, Mavri A, Morange PE: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-1579.
169. Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM: Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: Stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999; 84: 4097-4105. (Pubitemid 30644201)
170. Ayachi SE, Paulmyer-Lacroix O, Verdier M, Alessi MC, Dutour A, Grino M: 11 -Hydroxysteroid dehydrogenase type 1-driven cortisone reactivation regulates plasminogen activator inhibitor type 1 in adipose tissue of obese women. J Thromb Haemost 2006; 4: 621-627.
171. Darmon P, Dadoun F, Boullu-Ciocca S, Grino M, Alessi MC, Dutour A: Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. Am J Physiol Endocrinol Metab 2006; 291:E995-E1002.
172. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A: The fibrinolytic potential in patients with Cushing's disease: A clue to their hypercoagulable state. Blood Coag Fibrinolysis 1992; 3: 789-793. (Pubitemid 23026824)
173. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM: Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 2000; 23: 145-150. (Pubitemid 30218782)
174. Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G, Arosio M: Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 2000; 108: 486-492.
175. Devin JK, Blevins LS, Verity DK, Chen Q, Bloodworth JR, Jovington J, Vaughan DE: Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J Clin Endocrinol Metab 2007; 92: 3633-3639. (Pubitemid 47435349)
176. Van Der Lely AJ, Tschop M, Heiman ML, Ghigo E: Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-457. (Pubitemid 38780667)
177. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti B, Abribat T, Van Der Lely AJ, Ghigo E: Non-Acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004; 89: 3062-3065. (Pubitemid 38766409)
178. Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, Hosoda H, Kangawa K: Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 2007; 294:H426-H432.
179. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, McCormick ML, Sigmund CD, Tang C, Weintraub NL: Ghrelin inhibits proinflammatory responses and nuclear factor- B activation in human endothelial cells. Circulation 2004; 109: 2221-2226. (Pubitemid 38625400)
180. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, Cardillo C: Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112: 2986-2992. (Pubitemid 41612302)
181. Vestergaard ET, Andersen NH, Hansen TK, Rasmussen LM, Moller N, Sorensen KE, Sloth E, Jorgensen JO: Cardiovascular effects of intravenous ghrelin infusion in healthy young men. Am J Physiol Heart Circ Physiol 2007; 293:H3020-H3026. (Pubitemid 350106526)
182. Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kangawa K: Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovac Pharmacol 2002; 39: 779-783. (Pubitemid 34538806)
183. Copinschi G, Van Onderbengen A, L'Hermite-Baleriaux M, Mendel CM, Caufriez A, Leproult A, Bolognese JA, De Smet M, Thorner MO, Van Cauter E: Effects of a 7-day treatment with a novel, orally active, GH secretagogue, MK-677, on 24-hour GH profiles, insulin-like-growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab 1996; 81: 2776-2782. (Pubitemid 26323862)
184. Mozid AM, Tringali G, Forsling ML, Hendricks MS, Ajodha S, Edwards R, Navarra P, Grossman AB, Korbonits M: Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. Horm Metab Res 2003; 35: 455-459. (Pubitemid 37204560)
185. Hickey GJ, Drisko J, Faidley T, Chang CC, Anderson LL, Nicolich S, McGuire L, Rickes E, Krupa D, Feeney W, Friscino B, Cunningham B, Frazier E, Chen H, Laroque P, Smith RG: Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J Endocrinol 1996; 148: 371-380. (Pubitemid 26051530)
186. Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, Lombardi G, Camanni F: Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997; 82: 2439-2444. (Pubitemid 27337853)
187. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, Grossman AB: The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86: 881-887. (Pubitemid 32207510)
188. Pecori Giraldi F, Bucciarelli L, Saccani A, Scacchi M, Pesce S, Losa M, Cavagnini F: Ghrelin stimulates adrenocorticotrophic hormone (ACTH) secretion by human ACTH-secreting pituitary adenomas in vitro. J Neuroendocrinol 2007; 19: 208-212. (Pubitemid 46210948)
189. Ueberberg B, Unger N, Sheu SY, Walz MK, Schmid KW, Saeger W, Mann K, Petersenn S: Differential expression of ghrelin and its receptors (GHS-R1a) in various adrenal tumors and normal adrenal gland. Horm Metab Res 2008; 40: 181-188. (Pubitemid 351690521)
190. Caminos JE, Nogueiras R, Blanco M, Seoane LM, Bravo S, Alvarez CM, García-Caballero T, Casanueva FF, Diéguez C: Cellular distribution and regulation of ghrelin messenger ribonucleid acid in the rat pituitary gland. Endocrinology 2003; 144: 5089-5097. (Pubitemid 37378424)
191. Otto B, Tschop M, Heldwein W, Pfeiffer AFH, Diederich S: Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans. Eur J Endocrinol 2004; 151: 113-117. (Pubitemid 39117372)
192. Giordano R, Picu A, Pagotto U, De Iasio R, Bonelli L, Prodam F, Broglio F, Marafetti L, Pasquali R, Maccario M, Ghigo E, Arvat E: The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease. Eur J Endocrinol 2005; 153: 535-543. (Pubitemid 41556281)
193. McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE: Plasma ghrelin concentrations are decreased in insulinresistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab 2004; 89: 1630-1635. (Pubitemid 38507912)
194. Janssen JAM, van Der Toorn FM, Hofland LJ, van Koetsveld P, Broglio F, Ghigo E, Lamberts SW, Van Der Lely A: Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. Eur J Endocrinol 2001; 145: 711-716. (Pubitemid 33133677)
195. Jarkovska Z, Rosicka M, Marek J, Hana V, Weiss V, Justova V, Lacinova Z, Haluzik M, Haas T, Kresk M: Plasma levels of total and active ghrelin in acromegaly and growth hormone deficiency. Physiol Res 2006; 55: 175-181.
196. Ryber L, Obrink K, Houe N, Frystyk J, Jorgensen JO: Serum ghrelin levels are suppressed in hypopituitary patients following insulin-induced hypoglycaemia irrespective of GH status. Clin Endocrinol 2006; 65: 210-214. (Pubitemid 44079685)